Tag: Ocugen

On paper, Ocugen has everything a small-cap biotech investor could want: seven buy ratings, zero holds or sells, and a ...

Ocugen is racing against its own balance sheet. The biotech has mapped out a clinical calendar for 2026 that packs ...

A critical legal hearing scheduled for May 6 in Delaware could resolve a major uncertainty hanging over gene therapy developer ...

The biotech firm Ocugen is undergoing a significant strategic evolution, transitioning from a research-focused entity into a late-stage clinical developer ...

Biopharmaceutical firm Ocugen is transitioning from clinical development to the regulatory phase, with its lead gene therapy candidate approaching a ...

Positive results from a mid-stage clinical study have prompted several Wall Street research firms to revise their outlook on Ocugen, ...

A recent clinical trial update from Ocugen has prompted a significant reassessment of the company's prospects among Wall Street analysts. ...

In a counterintuitive market reaction, Ocugen's stock price declined significantly following the announcement of encouraging 12-month data from its Phase ...

In a surprising market reaction, shares of biotechnology firm Ocugen experienced a significant sell-off this week, even as the company ...

Ocugen, Inc. has bolstered its balance sheet without initiating a new formal funding round. The capital infusion came via the ...